نتایج جستجو برای: ژن brca2

تعداد نتایج: 19908  

Journal: :Cancer research 2012
Songmin Ying Freddie C Hamdy Thomas Helleday

PARP inhibitors are currently being used in clinical trials to treat BRCA1- or BRCA2-defective tumors, based on the synthetic lethal interaction between PARP1 and BRCA1/2-mediated homologous recombination (HR). However, the molecular mechanisms that drive this synthetic lethality remain unclear. Here, we show increased levels of Mre11, a key component of MRN (Mre11-Rad50-Nbs1) complex that play...

2017
Andrew A. Kelso Steven D. Goodson Leah E. Watts LeAnna L. Ledford Sarah M. Waldvogel J. Nathaniel Diehl Shivani B. Shah Amanda F. Say Julie D. White Michael G. Sehorn

Homologous recombination (HR) is a template-driven repair pathway that mends DNA double-stranded breaks (DSBs), and thus helps to maintain genome stability. The RAD51 recombinase facilitates DNA joint formation during HR, but to accomplish this task, RAD51 must be loaded onto the single-stranded DNA. DSS1, a candidate gene for split hand/split foot syndrome, provides the ability to recognize RP...

2016
Pedro Pinto Ana Peixoto Catarina Santos Patrícia Rocha Carla Pinto Manuela Pinheiro Luís Leça Ana Teresa Martins Verónica Ferreira Carla Bartosch Manuel R Teixeira

BRCA1 and BRCA2 mutations are responsible for hereditary breast and ovarian cancer, but they also confer an increased risk for the development of rarer cancers associated with this syndrome, namely, cancer of the pancreas, male breast, peritoneum, and fallopian tube. The objective of this work was to quantify the contribution of the founder mutations BRCA2 c.156_157insAlu and BRCA1 c.3331_3334d...

Journal: :medical journal of islamic republic of iran 0
amir mehrgou department of medical genetics and molecular biology, school of medicine, iran university of medical sciences, tehran, iran.سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (iran university of medical sciences) mansoureh akouchekian department of medical genetics and molecular biology, school of medicine, iran university of medical sciences, tehran, iran.سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (iran university of medical sciences)

many factors including genetic, environmental, and acquired are involved in breast cancer development across various societies. among all of these factors in families with a history of breast cancer throughout several generations, genetics, like predisposing genes to develop this disease, should be considered more. early detection of mutation carriers in these genes, in turn, can play an import...

Journal: :Human molecular genetics 2012
Clare Turnbull Sheila Seal Anthony Renwick Margaret Warren-Perry Deborah Hughes Anna Elliott David Pernet Susan Peock Julian W Adlard Julian Barwell Jonathan Berg Angela F Brady Carole Brewer Glen Brice Cyril Chapman Jackie Cook Rosemarie Davidson Alan Donaldson Fiona Douglas Lynn Greenhalgh Alex Henderson Louise Izatt Ajith Kumar Fiona Lalloo Zosia Miedzybrodzka Patrick J Morrison Joan Paterson Mary Porteous Mark T Rogers Susan Shanley Lisa Walker Munaza Ahmed Diana Eccles D Gareth Evans Peter Donnelly Douglas F Easton Michael R Stratton Nazneen Rahman

There have been few definitive examples of gene-gene interactions in humans. Through mutational analyses in 7325 individuals, we report four interactions (defined as departures from a multiplicative model) between mutations in the breast cancer susceptibility genes ATM and CHEK2 with BRCA1 and BRCA2 (case-only interaction between ATM and BRCA1/BRCA2 combined, P = 5.9 × 10(-4); ATM and BRCA1, P=...

Journal: :Cell 2003
Luke Hughes-Davies David Huntsman Margarida Ruas Francois Fuks Jacqueline Bye Suet-Feung Chin Jonathon Milner Lindsay A Brown Forrest Hsu Blake Gilks Torsten Nielsen Michael Schulzer Stephen Chia Joseph Ragaz Anthony Cahn Lori Linger Hilal Ozdag Elena Cattaneo E. S Jordanova Edward Schuuring David S Yu Ashok Venkitaraman Bruce Ponder Aidan Doherty Samuel Aparicio David Bentley Charles Theillet Chris P Ponting Carlos Caldas Tony Kouzarides

The BRCA2 gene is mutated in familial breast and ovarian cancer, and its product is implicated in DNA repair and transcriptional regulation. Here we identify a protein, EMSY, which binds BRCA2 within a region (exon 3) deleted in cancer. EMSY is capable of silencing the activation potential of BRCA2 exon 3, associates with chromatin regulators HP1beta and BS69, and localizes to sites of repair f...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Gong Yang Bin Chang Fan Yang Xiaoqing Guo Kathy Qi Cai Xue Sherry Xiao Huamin Wang Subrata Sen Mien-Chie Hung Gordon B Mills Sandy Chang Asha S Multani Imelda Mercado-Uribe Jinsong Liu

PURPOSE Aurora kinase A (Aurora-A) is known to regulate genomic instability and tumorigenesis in multiple human cancers. The underlying mechanism, however, is not fully understood. We examined the molecular mechanism of Aurora-A regulation in human ovarian cancer. EXPERIMENTAL DESIGN Retrovirus-mediated small hairpin RNA (shRNA) was used to silence the expression of Aurora-A in the ovarian ca...

2012
Yasunaga Yoshikawa Kazuhiko Ochiai Masami Morimatsu Yu Suzuki Seiichi Wada Takahiro Taoda Satomi Iwai Seishiro Chikazawa Koichi Orino Kiyotaka Watanabe

Mammary tumors are the most common tumor type in both human and canine females. Mutations in the breast cancer susceptibility gene, BRCA2, have been found in most cases of inherited human breast cancer. Similarly, the canine BRCA2 gene locus has been associated with mammary tumors in female dogs. However, deleterious mutations in canine BRCA2 have not been reported, thus far. The BRCA2 protein ...

Journal: :EBioMedicine 2015
Pari V Pandharipande Alvin Jeon Curtis R Heberle Emily C Dowling Chung Yin Kong Daniel C Chung William R Brugge Chin Hur

BACKGROUND BRCA2 mutation carriers are at increased risk for multiple cancers including pancreatic adenocarcinoma (PAC). Our goal was to compare the effectiveness of different PAC screening strategies in BRCA2 mutation carriers, from the standpoint of life expectancy. METHODS A previously published Markov model of PAC was updated and extended to incorporate key aspects of BRCA2 mutation carri...

2010
Logan C. Walker Bryony A. Thompson Nic Waddell kConFab Investigators Sean M. Grimmond Amanda B. Spurdle

A large number of rare sequence variants of unknown clinical significance have been identified in the breast cancer susceptibility genes, BRCA1 and BRCA2. Laboratory-based methods that can distinguish between carriers of pathogenic mutations and non-carriers are likely to have utility for the classification of these sequence variants. To identify predictors of pathogenic mutation status in fami...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید